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Abstract In a prospective multi-center observational
study, we evaluated the frequency, severity, and impact on
activities of daily living (ADL) of adverse effects (AEs) of
high-dose intravenous methylprednisolone (IVMP) in
relapsing remitting multiple sclerosis (MS) patients with a
relapse. Online self-report questionnaires stating IVMP’s
most common AEs were completed at baseline, the 2nd
day of treatment, and 1 day and 1 week after treatment.
Eighty-five patients were included, 66 completed the
baseline questionnaire, and 59 completed at least one post-
baseline questionnaire. Patients reported on average 4
(median) AEs; two (3.4 %) reported no AE. Most frequent
was change in taste (61 %), facial flushing (61 %), sick/
stomach pain (53 %), sleep disturbance (44 %), appetite
change (37 %), agitation (36 %), and behavioral changes
(36 %). Of all AEs, 34.3 % were severe and 37.9 %
impacted on ADL. A 3-day course resulted in 4 (median)
AEs and a 5-day course in 7. All patients with high disease
impact had two or more AEs, compared with 79 % of those
with low impact (p\ 0.01). Of patients with high dis-
ability, 45 % had severe AEs, compared with 16 % of
those with low disability. Severe central nervous system
(CNS)-related AEs occurred two times more frequently in
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patients with high disease impact, and two-and-a-half times
more frequently in patients with high disability. Therefore,
in virtually all patients, high-dose IVMP leads to AEs, with
about one of three AEs being severe with impact on ADL.
Patients with high disease impact or high disability may
experience more (severe) AEs, due to a higher occurrence
of severe CNS-related AEs.
Keywords Multiple sclerosis  High dose 
Methylprednisolone  Adverse effect  Side effect 
Patient-reported
Introduction
Multiple sclerosis (MS) is a chronic disease of the central
nervous system (CNS), in which immune-mediated
inflammation and degeneration lead to loss of myelin and
axons. In four out of five patients, the disease course is
initially characterized by relapses and remissions: relaps-
ing-remitting MS (RRMS) [1]. Most patients fully recover
after a relapse, but this can take weeks or months [2].
Treatment with high-dose methylprednisolone shortens the
relapse duration and increases the chances of recovery [3].
A European Federation of Neurological Societies task
force recommends treatment with intravenous (iv) or oral
methylprednisolone in a dose of at least 500 mg daily for
5 days or iv methylprednisolone (IVMP) 1 g daily for
3 days [3].
Methylprednisolone, like other corticosteroids, is asso-
ciated with a number of adverse effects (AEs), affecting the
skin, skeleton, muscles, eyes, CNS, electrolytes, metabo-
lism, and the endocrine, cardiovascular, immune, and
gastrointestinal systems, often in a dose-dependent manner
[4]. In the USA in 2004, corticosteroids were the most
common specific cause for drug-related AEs, accounting
for 10.3 % of all drug-related AEs and 141,000 hospital
stays [5]. Although most serious AEs are related to the
long-term oral use, short-term steroid-induced symptoms
are frequent, especially with high-dose treatment needed to
treat relapses [6].
Patient-reported outcomes (PROs) receive growing
attention in drug research. PROs are measurements of any
aspect of a patient’s health status that comes directly from
the patient and can be used to evaluate how a treatment
affects patients’ functioning and well-being [7]. Studies
using PROs to evaluate the AEs of long-term oral corti-
costeroid treatment showed that patients experience an
average of 2.1–2.3 treatment-related symptoms [8, 9].
Most studies on IVMP treatment in MS did not focus on
AEs [10, 11]. Despite their frequent occurrence, the
severity of IVMP’s AEs is thought to be minor, as they
seldom require hospitalization or medical interventions.
However, from a patient perspective, this may be ques-
tioned, as studies of corticosteroids in general show that
they may bother patients and affect the quality of life [9].
In patients with immune thrombocytopenic purpura, AEs
of corticosteroids were found to be more bothersome from
the patients’ perspectives than from the doctors’ perspec-
tives [9]. Moreover, in MS patients, the distress from CNS-
related AEs, like mood change, behavioral change, and
sleep disturbance, may add to the burden of MS-related
CNS symptoms.
In view of the above, we performed the patient-reported
adverse effects of methylprednisolone for relapse treatment
in multiple sclerosis (FEEL) study. We specifically asses-
sed from a patient perspective the occurrence, severity,
bothering, and impact of AEs during and after high-dose
IVMP treatment of an MS relapse. We hypothesized that
more (severe) AEs would be reported by patients treated
with a 5-day course than by those treated with a 3-day
course, and by patients who had not been treated with
IVMP in recent years, due to them being less acquainted
with IVMP’s AEs. We also expected that CNS-related AEs
would be more frequent and more severe in patients with
high disease impact and high disability, as we thought it
likely that patients with more MS-related CNS dysfunction
might be especially susceptible to (severe) AEs affecting
the CNS.
Methods
Study design and organization
The FEEL study was a prospective, patient-centered, web-
based, multi-center study in 15 MS centers and MS spe-
cialized neurological practices in The Netherlands. The
primary objective was to investigate in patients with
RRMS and clinically isolated syndrome (CIS) who were
treated with IVMP for a relapse, the frequency, severity,
bothering, and impact on activities of daily living (ADL) of
AEs; the secondary objective was to investigate the rela-
tionship between AEs and the duration of the treatment
course (3-day vs. 5-day course), IVMP treatment in the
previous two years, and MS-related disease impact and
disability. Methylprednisolone was prescribed by the
treating neurologist as per regular care and dispensed by
the pharmacy as a commercial drug.
The study data were collected using the LimeSurvey
software, an open source online application for conducting
surveys. Before including the first patient, the MS4
Research Institute’s study platform was extensively tested.
Responses were automatically captured. To protect the
personal data from unauthorized access, various mecha-
nisms were used to comply with European Union
1642 J Neurol (2016) 263:1641–1651
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regulations concerning online medical data, including the
use of a personal username and a strong password, sepa-
ration in the database of personal information from the
answers to the questions, each screen having a username
and password protection, virtual private network tunneling,
256-bits encryption, and the encryption of the participants’
identities via unique 15 digits codes. Automated com-
pleteness checks were done before questionnaires could be
submitted. The respondents saw an overview of all ques-
tions and answers before submission, and they could
change the answers before submitting. After submission
changes were no longer possible. The help desk (MH)
contacted patients by phone in case that they did not suc-
ceed in completing the questionnaires. In some cases,
questionnaires were completed in paper format at the
hospital or at the patients’ home; these were then collected
by the site staff, sent to the MS4 Research Institute, and
entered by one of the researchers (MH).
Inclusion procedure and ethical aspects
The inclusion criteria were: (1) diagnosis RRMS or CIS,
(2) confirmed relapse, (3) indication for methylpred-
nisolone treatment, (4) willing and able to comply with the
protocol, (5) written informed consent, and (6) having
access to the internet. During the course of the study, this
last criterion was made not applicable, as some of the
hospitals preferred to provide the questionnaires in paper
form to the patients. The exclusion criteria were: (1) con-
tra-indication for methylprednisolone as defined in the
Summary of Product Characteristics, (2) corticosteroid
treatment in the previous 30 days, (3) pregnancy or lacta-
tion, (4) participation in another study, and (5) progressive
MS.
In the study centers, patients with RRMS or CIS who
were to start IVMP treatment for a relapse were informed
about the study by their treating neurologist or the MS
nurse. Patients were informed that they had the right to
withdraw consent at any time without prejudice to the
neurological treatment or care. After having given their
consent patients received a personal code and logged on to
the website of the MS4 Research Institute (http://www.
ms4ri.nl) to choose a username and password.
The study protocol was presented to the ethical com-
mittee Medisch Ethische Toetsing Onderzoek Patie¨nten en
Proefpersonen (METOPP) (METC nr. M501) in Tilburg,
The Netherlands, and the committee concluded that a
review was not indicated, as the study did not qualify for
being tested according to the Dutch Medical Research
Involving Human Subjects Act of 1999 (http://wetten.
overheid.nl/BWBR0009408) [12]. The study was per-
formed in agreement with the Declaration of Helsinki
(Ethical Principles for Medical Research Involving Human
Subjects version 2013; 64th World Medical Association
General Assembly, Fortaleza, Brazil, October 2013) (http://
www.wma.net) and the Wet medisch-wetenschappelijk
onderzoek met mensen (WMO) (Dutch Medical Research
Involving Human Subjects Act) (www.wetten.overheid.nl/
BWBR0009408).
The study was financially supported by to-BBB Tech-
nologies BV, Leiden, The Netherlands.
Assessment of adverse effects
AEs were assessed via the Methylprednisolone Adverse
Effects Questionnaire (MPAEQ). The MPAEQ inquired
about the presence of 15 symptoms that we had previously
identified in the literature as being most commonly asso-
ciated with a short-term methylprednisolone treatment or
as very common glucocorticosteroid AEs [3, 9, 10, 13]:
facial flushing, feeling sick or having stomach pain, change
in taste, change in appetite, sleep disturbance, feeling
agitated, feeling angry or bad tempered, feeling depressed,
being overoptimistic, behavioral change, muscle weakness,
muscle cramps, skin change or delayed wound healing,
palpitations, and acne. For each of the 15 items, if an
answer was affirmative, then the severity and botheration
were quantified (Not at all, A little, Quite a lot, A lot), and
the impact on ADL was assessed (Yes, No). Moreover,
general questions were asked about the overall health
condition (related to MS, to AEs, or both) regarding
botheration about the health condition, the health condi-
tion’s impact on ADL, and the health condition’s impact on
social activities.
The MPAEQ was completed before the start of the
IVMP treatment course, at the 2nd day of the treatment,
and 1 day and 1 week after the end of the treatment.
Therefore, for a 3-day course, the post-baseline assess-
ments were on days 2, 4, and 10, and for a 5-day course,
the post-baseline assessments were on days 2, 6, and 12.
The baseline MPAEQ was completed at the 1st day of
treatment before the first infusion or at the most 2 days
earlier. An AE was defined as a new symptom or a
worsening of a pre-existing symptom occurring after the
start of treatment. This approach enabled the identifica-
tion of differences between the pre-treatment and follow-
up assessments as AEs, and prevented pre-existent
symptoms of MS, relapse or concomitant disease from
being wrongly associated with the IVMP treatment. An
AE was considered severe when the intensity was ‘A lot’
or ‘Quite a lot’ at least once; otherwise, it was mild; an
AE was considered bothering when the response to this
question was ‘A lot’ or ‘Quite a lot’ at least once. We
considered sleep disturbance, feeling agitated, feeling
angry or bad tempered, feeling depressed, being overop-
timistic and behavioral change as CNS-related AEs, and
J Neurol (2016) 263:1641–1651 1643
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facial flushing, feeling sick or having stomach pain,
change in taste, change in appetite, muscle weakness,
muscle cramps, skin change or delayed wound healing,
palpitations, and acne as not CNS-related AEs. One day
and 1 week after the end of treatment, questions were
asked regarding weight increase, infections, use of an iv
cannula, premature discontinuation (only 1 week after
treatment) and hospitalization (only 1 week after treat-
ment). In addition, the following demographic and disease
characteristics were collected at baseline: date of birth,
sex, disease modifying treatment, number of relapses, and
number of IVMP courses in the last two years.
Neurologists were asked to provide baseline information
on the diagnosis, disease course, disease duration, location
of treatment, treatment schedule, and the Expanded Dis-
ability Status Scale (EDSS) score (optional), and to report
any IVMP treatment-related diagnosis 1 week after the end
of treatment, using the same study website as the patients.
Assessment of disease impact and disability
The impact of MS was assessed via the multiple sclerosis
impact profile (MSIP) [14, 15]. The MSIP includes 36
questions assessing disability in the domains muscle and
movement functions (MMF), excretion and reproductive
functions (ERF), basic movement activities (BMA),
activities of daily living (ADL), participation in life situ-
ations (PLS), environmental factors (EF), and mental
functions (MF), and the symptoms fatigue, pain, speech,
and vision [14, 15]. The MSIP yields validated domain and
symptom scores, where higher scores indicate a worse
condition. We considered that the domains MMF, ERF,
and MF, and the symptoms speech and vision reflect
functions and specific symptoms relating directly to the
CNS, and that the domains BMA, ADL, PLS, and EF, and
the symptoms fatigue and pain reflect activities and general
symptoms that are potentially also influenced by external
factors. Therefore, for the purpose of this study, we con-
ceived the MSIP Functions and Specific Symptoms
(MSIP–FSS) score, based on the scores of the domains
MMF (0–16), ERF (0–12), and MF (0–16), and of the
symptoms speech (0–4) and vision (0–4). By use of
the formula (MMF*1.25 ? ERF*1.67 ? MF*1.25 ?
Speech*5 ? Vision*5), the MFIS–FSS score was calcu-
lated (minimum 0, maximum 100).
Disability was measured optionally by use of the EDSS
[16]. The EDSS is widely used in MS and is based on a
neurological examination that provides the basis for the
assessment of several functional systems (pyramidal,
cerebellar, brainstem, sensory, bowel and bladder, visual,
and cerebral or mental) that, according to predefined
algorithms, contribute to the EDSS score [16].
Statistical aspects
No statistical sample size calculation was performed for
this observational study. We aimed to include 100 patients,
a number that was determined by practical considerations
and was considered appropriate to achieve the stated
objectives. Descriptive statistics were used for the evalu-
ation of the primary outcomes of this study. In some cases,
p values were calculated to determine the relevance of
observed effects with respect to the secondary outcomes.
Results
Patients
Between January 2013 and April 2014, 85 patients were
included, i.e., signed the informed consent form (Fig. 1).
Seventy (82.4 %) patients provided baseline information
on demographic and disease characteristics. Fifty-four
(77.1 %) were female, 16 (22.9 %) male; mean [standard
deviation (SD)] age was 44.9 (10.9) years (minimum 25,
maximum 67). Twenty-nine (41.4 %) patients used disease
modifying treatment, 38 (54.3 %) did not [missing 3
(4.3 %)]. Fifty-three (75.7 %) had experienced one or more
relapses and 42 (60.0 %) had received one or more IVMP
treatment courses during the last 2 years. The MPAEQ was
completed at baseline, the 2nd day of treatment, and 1 day
Paents enrolled
N = 85 (100%)
Data received from 
neurologists
N = 62 (73%)
Baseline informaon 
received from paents 
N = 70 (82%)
MPAEQ – before 
treatment (baseline)
N = 66 (78%)
MPAEQ – 2ndday of 
treatment 
N = 62 (73%)
MPAEQ – 1 day aer 
end of treatment
N = 61 (72%)
MPAEQ – 7 days aer 
end of treatment
N = 59 (69% )
All data received
N = 47 (55%)
Fig. 1 Subject disposition. Numbers (percentages) of patients who
were included and who completed the Methylprednisolone Adverse
Effects Questionnaire (MPAEQ) at the different time points
1644 J Neurol (2016) 263:1641–1651
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and 1 week after the end of treatment by 66 (77.6 %), 62
(72.9 %), 61 (71.8 %), and 59 (69.4 %) patients.
Neurologists provided information on 62 (72.9 %)
patients. Fifty-one (82.3 %) patients had RRMS or CIS,
and four (6.4 %) progressive MS [information missing in 6
(9.7 %)]. Fifty-two (83.9 %) had a relapse, and four
(6.5 %) had no relapse [missing 6 (9.7 %)]. The mean (SD)
disease duration was 8.95 (7.48) years (minimum 0.0,
maximum 28.0), and the mean (SD) EDSS score (N = 32)
was 3.0 (1.7) (minimum 0.5, maximum 6.5). Complete
patient-reported and neurologist-reported data—with
exception of the optional EDSS score—were available in
47 (55.3 %) patients.
Treatment
IVMP was given in an outpatient clinic, in a hospital and at
home in 36 (58.1 %), 18 (29.0 %) and 1 (1.6 %) patient(s),
respectively [missing 7 (11.3 %)]. The treatment course
was 3 days in 36 (58.1 %) and 5 days in 20 (32.3 %)
patients (missing 6 [9.7 %]). The daily IVMP dose was
1000 mg in 49 (79.0 %) and 500 mg in 7 (11.3 %) patients
[missing 6 (9.7 %)]. The treatment was completed in 40
(64.5 %) patients and not completed in 1 (1.6 %) [missing
21 (33.9 %)]. The mean (SD) daily IVMP dose (N = 56)
was 937.5 (166.9) mg (minimum 500, maximum 1000), the
mean (SD) total dose (N = 56) was 3419.6 (952.4) mg
(minimum 1500, maximum 5000), and the mean (SD)
durations (per day) of the infusions were between 1.32




Fifty-nine patients completed the MPAEQ at baseline and
at one or more time points after the start of treatment.
They reported a total of 306 AEs during and within
1 week after the end of treatment. On average, a patient
reported 4 (median) (minimum 0, maximum 12) of the 15
AEs stated in the questionnaire; two (3.4 %) patients
reported no AE. The percentages of patients reporting the
various AEs are shown in Fig. 2. Most frequent AEs were
change in taste (61 %), facial flushing (61 %), feeling
sick or having stomach pain (53 %), and sleep distur-
bance (44 %). The numbers (percentages) of patients
reporting AEs at the 2nd day of treatment, and at 1 day
and 1 week after the end of treatment, are presented in
Table 1.
Severity, bothering, and impact on activities of daily living
The numbers (percentages) of patients reporting one or more
severe AEs, bothering AEs, and AEs with impact on ADL at
the various time points are shown in Table 1. Of all AEs,
34.3 % (N = 105) were severe. The percentages of patients
reporting a given AE and considering it severe are presented
in Fig. 3. Twenty-two (37.3 %) patients had no severe AE,
but on average, one (median) (minimum 0, maximum 7)
severe AE was reported per patient. The most frequent severe
AEs were sleep disturbance (31 %), muscle weakness
(22 %), feeling sick or having stomach pain (20 %), and
being agitated (19 %). In contrast, overoptimistic feelings
(0 %), acne (2 %), and skin change or delayed wound
healing (3 %) were rarely severe, also compared with their
overall occurrence (22, 20, and 20 %, respectively).
Seventy-nine AEs (25.8 %) were rated as bothering.
Thirty (50.8 %) patients reported at least one bothering AE
(median 0, minimum 0, maximum 6).
One-hundred-and-sixteen AEs (37.9 %) had an impact
on ADL, and 38 (64.46 %) patients reported at least one
AE with an ADL impact (median 1, minimum 0, maximum
8). Figure 4 shows the percentages of patients reporting a
given AE that affected their ADL. Sleep disturbance
(29 %), muscle weakness (27 %), feeling sick or having
stomach pain (20 %), and feeling agitated (20 %) were the
most commonly reported AEs that impacted ADL.
Other and serious adverse effects
One week after treatment, 17 patients (28.8 %) reported to
have gained weight of 1 kg or more and six patients
(10.2 %) reported to have suffered an infection (three
bladder infections). Five patients (8.5 %) stated that they
considered refusing IVMP treatment every time they are
treated, and seven (11.9 %) reported to sometimes consider
refusing treatment. As much as 57 patients (93.4 %)
reported the use of an intravenous cannula during the
treatment period, for seven patients (11.4 %), this was
bothering and for 21 (34.4 %), it interfered with their ADL.
Neurologists reported to have made an IVMP treatment-
related diagnosis in three (4.8 %) patients (acute coronary
syndrome, diabetes mellitus, one unspecified) out of 62;
however, for 21 patients (33.9 %), no information was
provided.
3-day vs. 5-day course
The number of AEs in the 3 days 1000 mg/day group
(N = 30) was 153, yielding a median of 4 AEs per patient































Skin change/delayed wound healing
Muscle cramps
% of paents (N=59)
Fig. 2 Percentages of patients
experiencing a given adverse
effect (AE). AEs are marked as
CNS-related (red bar) and not
CNS-related (blue bar)
Table 1 Numbers (percentages) of patients who reported adverse
effects (AEs), severe AEs, bothering AEs, and AEs with impact on
activities of daily living (ADL) at the 2nd day of an intravenous
methylprednisolone (IVMP) treatment course, 1 day after the end of
the treatment course, and 1 week after the end of the treatment course
Day 2 IVMP (N = 59) (%) 1 day after IVMP (N = 58) (%) 1 week after IVMP (N = 56) (%)
No AE 13 (22) 4 (7) 16 (29)
One AE 13 (22) 8 (14) 14 (25)
Two or more AEs 33 (56) 46 (79) 26 (46)
Severe AE(s) 46 (30) 60 (29) 41 (33)
Bothering AE(s) 34 (22) 51 (25) 30 (24)
AE(s) with impact on ADL 39 (25) 69 (34) 51 (41)
Fig. 3 Percentages of patients
experiencing a given adverse
effect (AE) and considering it
severe. AEs are marked as CNS-
related (red bar) and not CNS-
related (blue bar)
1646 J Neurol (2016) 263:1641–1651
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(minimum 1, maximum 11). In the 5 days 1000 mg/day
group (N = 12), the number of AEs was 85, which yields a
median of 7 AEs per patient (minimum 2, maximum 12).
The number of severe AEs was 49 (32.0 % of all AEs) and
23 (27.1 % of all AEs) in these two groups, respectively.
Treated in previous two years vs. not treated
Comparing the frequencies of (severe) AEs in patients who
had been treated with IVMP in the previous 2 years vs.
those without such treatment, we found no differences. In
the former group (N = 34), a total of 176 AEs (median 4
AEs per patient, minimum 0, maximum 12) and 56 (31.8 %
of all AEs) severe AEs were observed. The latter group
(N = 22) experienced 118 AEs (median 5 AEs per patient,
minimum 0, maximum 12) and 47 (39.8 % of all AEs)
severe AEs.
High vs. low disease impact and disability
In patients (N = 65) who completed the MSIP, the mean
(SD) MSIP–FSS score was 16.80 (9.32) (median 15.42,
minimum 1.25, maximum 37.94). We evaluated the MSIP–
FSS by exploring the relationship between this patient-re-
ported score on disease impact and the doctor-reported
EDSS score on disability. In patients (N = 15) with an
EDSS score \3.0, the mean (SD) MSIP–FSS score was
12.28 (9.54) (median 10.42, minimum 1.25, maximum
36.68), and in patients (N = 12) with an EDSS score C3.0,
it was 17.89 (9.30) (median 15.43, minimum 9.59, maxi-
mum 33.35). The Wilcoxon two-sample test found a rele-
vant difference (p = 0.083) between an EDSS score of\3
and C3 for the MSIP–FSS score. Moreover, the Spearman
correlation coefficient between the MSIP–FSS score and
the EDSS score was 0.59, showing a moderate relationship
between the two scales.
A relevant difference was found between patients with a
low (B15) and a high ([15) MSIP–FSS score regarding the
number of patients with two or more AEs: 78.6 vs. 100 %
(p\ 0.01, Fisher’s exact test) (Table 2). Moreover,
patients with a high EDSS score (N = 11) reported 21
severe AEs (44.7 % of all AEs), whereas patients with a
low EDSS score (N = 15) reported 13 severe AEs (15.7 %
of all AEs).
Relationship between CNS-related adverse effects
and disease impact and disability
With respect to the total number of CNS-related AEs, no
differences were found between patients with high vs. low
disease impact or disability In contrast, the total number of
severe CNS-related AEs in patients (N = 30) with high
disease impact was 31, whereas the number of severe CNS-
related AEs in patients (N = 28) with low disease impact
was 13 (Additional file). Likewise, the total number of
severe CNS-related AEs in patients (N = 11) with high
disability was 12, whereas the total number of severe CNS-
related AEs in patients (N = 15) with low disability was 5.
Similar differences were not found with respect to severe
not CNS-related AEs. For more information about CNS-
related vs. not CNS-related AEs with respect to disease
impact and disability, see Additional file.
Overall health condition: botheration, impact on ADL,
and impact on social activities
The data on the botheration about the overall health con-
dition—related to MS, to AEs, or both—and about the
Fig. 4 Percentages of patients
experiencing a given adverse
effect (AE) and stating that it
affected their activities of daily
living (ADL). AEs are divided
into CNS-related (red bar) and
not CNS-related (blue bar)
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health condition’s impact on ADL and social activities
suggest that the health condition was highest at the 2nd day
of treatment, whereas at 1 day and 1 week after IVMP, it
was approximately as low as before treatment (Table 3). It
thus seems that the combined burden of MS symptoms and
IVMP’s AEs after treatment equals the burden of MS
disease during a relapse before IVMP treatment.
Discussion
During and within 1 week after high-dose IVMP treatment,
patients reported on average five of the most common AEs;
only two (3.4 %) patients reported no such AE. Most fre-
quent were change in taste, facial flushing, and feeling sick
or having stomach pain. About one-third of the AEs were
considered severe, and on average, each patient suffered
from one severe AE. The most common severe AEs were
sleep disturbance, muscle weakness, feeling sick or having
stomach pain, and being agitated, which were reported by
one-third to one-fifth of the patients. Also, one out of four
AEs were bothersome, one out of three AEs had an impact
on ADL, and a longer treatment course, viz. a higher
cumulative dose was associated with more AEs.
These observations in daily practice are in line with a
recent study in 49 MS patients treated in a randomized
controlled trial with iv or oral methylprednisolone for a
relapse [10]; all patients except one reported at least one
AE, more than half of the patients reported at least one very
bothersome AE, and the prevalence of the eight commonly
attributed self-reported AEs was significantly associated
with the cumulative and average corticosteroid dose [10].
Another randomized, double-blind, controlled study com-
paring iv with oral methylprednisolone in RRMS patients
with a relapse, reported a 97 % frequency of AEs in both
groups [17]; the most common AEs reported in the IVMP
group where metallic taste (81 %), insomnia (64 %),
headache (64 %), hot flashes (59 %), epigastric pain































No AE 2 (3.4 %) 0 0 1 (4.5 %) 1 (2.9 %) 0 1 (9.1 %) 2 (7.1 %) 0
One AE 4 (6.8 %) 2 (6.7 %) 0 1 (4.5 %) 3 (8.8 %) 2 (13.3 %) 0 4 (14.3 %) 0
2 or more
AEs
53 (89.8 %) 28 (93.3 %) 12 (100 %) 20 (91.0 %) 30 (88.3 %) 13 (86.7 %) 10 (90.9 %) 22 (78.6 %) 30 (100 %)
AEs per patient
Median 4 4 7 5 4 5 4 4 5
Range 0–12 1–11 2–12 0–12 0–12 1–12 0–9 0–12 2–11
Total number
of AEs
306 153 85 118 176 83 47 135 169
Severe AEs 105 (34.3 %) 49 (32.0 %) 23 (27.1 %) 47 (39.8 %) 56 (31.8 %) 13 (15.7 %) 21 (44.7 %) 44 (32.6 %) 61 (36.1 %)




116 (37.9 %) 52 (34.0 %) 36 (42.4 %) 50 (42.4 %) 66 (37.5 %) 27 (32.5 %) 18 (38.3 %) 51 (37.8 %) 65 (38.5 %)
IVMP intravenous methylprednisolone, EDSS expanded disability status scale score, MSIP-FSS multiple sclerosis impact profile-functions and
specific symptoms score
Table 3 Numbers (percentages) of patients with botheration about
multiple sclerosis (MS) symptoms or intravenous methylprednisolone
(IVMP) adverse effects (AEs), and of patients experiencing an impact
of symptoms or AEs on activities of daily living (ADL) and on social
activities, before treatment, at the 2nd day of treatment, and 1 day and
1 week after the end of treatment
MS symptoms, AEs Baseline (N = 66)
(%)
Day 2 IVMP (N = 62)
(%)
1 day after IVMP (N = 61)
(%)
1 week after IVMP (N = 59)
(%)
Botheration 27 (40.9) 18 (29.0) 22 (36.1) 23 (39.0)
Impact on ADL 26 (39.4) 18 (29.0) 20 (32.8) 25 (42.4)
Impact on social
activities
25 (37.9) 19 (30.6) 21 (34.4) 22 (37.3)
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(45 %), and anxiety (37 %), which are similar to those
reported by the patients in our study even though a dif-
ferent wording of AEs was used [17].
A finding that to our knowledge has not been reported
previously is the association between AEs and disease
impact and disability. On further analyses, it seemed that
this association may be due to severe CNS-related AEs
occurring two times more frequently in patients with high
disease impact, and two-and-a-half times more frequently
in patients with high disability, than in those with low
disease impact and low disability, respectively. In fact, it
was one of the study’s hypotheses that patients with more
CNS dysfunction, due to the MS disease process, would be
more susceptible to methylprednisolone interference with
the CNS function. After all, glucocorticoids do influence
the function of neurons and microglia [18], and since long
corticosteroids have been associated with CNS-related
AEs, especially psychological ones [19]. In disease states
with excessive endogenous corticosteroid levels, depres-
sion, anxiety, and change in behavior are seen in more than
half of the patients [20]. Yet, a review on the chronic use of
corticosteroids in neuro-oncological patients did not men-
tion CNS-related AEs as frequently occurring [21]. It may
be important for doctors to know that higher MS disability
and disease impact may be associated with more severe
CNS-related AEs, as the impact rate of CNS-related AEs
on patients’ ADL is twice that of not CNS-related AEs (57
vs. 27 %).
About one out of three AEs were severe. The percent-
ages of AEs that bothered patients and that impacted on
their ADL (26 and 38 %) were of the same magnitude as
that of severe AEs, which seems to confirm the clinical
relevance of severe AEs. In contrast, Lienert et al. con-
cluded recently that in CIS and MS patients, IVMP therapy
was well tolerated without severe side effects. However,
their patients received a lower cumulative dose (5 days
500 mg) than our patients. Moreover, patients were
apparently not asked to self assess the severity of their AEs.
Similarly, Weusten et al. evaluated the side effects of
corticosteroid pulse therapy in patients with active
rheumatoid arthritis and stated that in most cases the side
effects were mild, however, without using a patient-based
definition of severe or mild [22].
Our data show that the combined burden of MS-related
symptoms and IVMP’s AEs did not substantially differ
between baseline and 1 week after treatment. This obser-
vation suggests that 1 week after treatment the likely
decrease in the burden of MS disease, due to relapse
recovery [23], is neutralized by the burden of still existing
AEs of the IVMP treatment.
Our study has several limitations, which we like to
address here. First, only 66 (77.6 %) of the 85 included
patients completed the baseline MPAEQ, and post-baseline
data were obtained in 59 of the 66 patients (89.4 %).
Possibly patients with more (severe) AEs did not complete
a post-baseline questionnaire. Yet, the size of our study
group compares relatively well with those in similar studies
[10, 24]. Second, we did not include AEs in the question-
naire that have been found by others to be frequently
reported by patients, like headache (54 % in Ramo-Tello
et al.), dry mouth (42 % in Lienert et al.), and sweating
(27 % in Lienert et al.). This may have resulted in an
underestimation of the incidence of common (severe) AEs.
Third, data on CNS dysfunction were obtained in a limited
number of patients (EDSS, N = 32) or by means of a not
validated overall score (MSIP–FSS) [14, 15]. Fourth, the
numbers of patients in the subgroups for analyses of the
secondary objective were rather small, which necessitates a
cautious interpretation and may stimulate others to repro-
duce our results. Fifth, in an observational setting, it is
challenging to differentiate AEs from symptoms originat-
ing from the underlying disease process [19]. Moreover,
the hope of a good outcome after steroid treatment or the
occurrence of an early improvement may have influenced
the report and assessment of AEs. By asking the same
predefined questions before, during, and after treatment
using a neutral wording, we tried to assess the AEs in a
conservative way. Sixth, the study group was less homo-
geneous than envisaged, as four progressive patients were
treated to halt progression; neither does the study inform
about AEs in progressive patients with active disease [25].
Given the potential negative impact of IVMP treatment
doctors and nurses should counsel patients about possible
AEs [26]. However, the information given may be biased
or limited in scope. Until recently, the literature on IVMP
was dominated by medical diagnoses of rare serious AEs.
This is in line with the discrepancy that we observed
between the numbers of AEs reported by patients and by
doctors: the neurologists reported three IVMP-related
diagnoses in patients on whom information was provided
(N = 41), whereas 306 AEs were reported by the patients
(N = 59) themselves.
Further clinical research is needed into the effectiveness
and the risks associated with methylprednisolone in MS
relapses, as this would enable better informed and more
precise treatment recommendations [27]. PROs have
already enabled a better evaluation of relapse burden from
the patient perspective in terms of quality of life and
functional ability [28–30]. A similar approach, using PROs
to evaluate the burden of AEs, seems equally important, to
enable a clinically relevant benefit-risk assessment of
short-term corticosteroid treatment, e.g., in our study, one
out of five patients (sometimes) considered refusing IVMP
treatment because of AEs.
We hope that our study contributes to better informed
choices with respect to high-dose IVMP treatment, by
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quantitatively and comprehensively informing on the
occurrence, severity, and impact of the most common AEs
from the patient perspective.
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